There's an article in today's NBR with some comments from one of Craig's analyst's regarding the murky nature of any final Novitas outcome from the revised process. Besides the new Novitas process another "significant tail risk has emerged" which involves the FDA intending to issue draft regulatory requirements by August this year for Laboratory Developed Tests which until now haven't required FDA approval.